Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03349957 | TACE for HCC by TANDEM and Idarubicin(TANDEM-IDA) | completed | — | 98 | University Hospital, MontpellierOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01135056 | Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)(SIRveNIB) | unknown | Phase 3 | 360 | Singapore General HospitalOTHER | 12 | Apr 24, 2018 |
| clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | withdrawn | Phase 3 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT03132740 | Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma | unknown | — | 2,000 | Zhujiang HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT03191123 | Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor | unknown | N/A | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT03493763 | Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT03490461 | Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation | completed | — | 350 | Yonsei UniversityOTHER | 1 | Apr 6, 2018 | clinicaltrials |
| NCT01829035 | A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC | completed | Phase 3 | 339 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03476421 | R1vascular Hepatectomy for HCC Patients | completed | — | 327 | Humanitas Clinical and Research CenterOTHER | 0 | Mar 26, 2018 | clinicaltrials |
| NCT01490203 | Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma(LiFE) | completed | — | 71 | Seoul National University HospitalOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT03468231 | HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2018 | clinicaltrials |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis(PACT CREATE 3) | withdrawn | N/A | 0 | VA Office of Research and DevelopmentFED | 1 | Feb 26, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | terminated | Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT03430635 | Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma | completed | — | 40 | Humanitas Clinical and Research CenterOTHER | 0 | Feb 13, 2018 | clinicaltrials |
| NCT03416803 | A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma | unknown | N/A | 150 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01956864 | Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01850316 | Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy | unknown | N/A | 13 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03175705 | Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC | unknown | Phase 1 | 18 | Beijing YouAn HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02525380 | Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 4 | 30 | Seoul National University HospitalOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT03398122 | Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma(HCC) | unknown | N/A | 248 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01839630 | Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China(SUCCESS) | completed | — | 302 | BayerINDUSTRY | 1 | Dec 20, 2017 | clinicaltrials |
| NCT02311205 | Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)(COTSOM) | unknown | Phase 2 | 55 | Asan Medical CenterOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | withdrawn | Phase 2 | 0 | Delcath Systems Inc.INDUSTRY | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03356535 | Metabolic Signature of Healthy Lifestyle and HCC | completed | — | 294 | International Agency for Research on CancerOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT02003339 | Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium(ICY) | completed | N/A | 25 | Center Eugene MarquisOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | terminated | Phase 2 | 1 | Justin SimsOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00370513 | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03340636 | Residual Plasma Concentration of Sorafenib and Adverse Events in CHC(PharmacoCHC) | unknown | — | 60 | University Hospital, CaenOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03337841 | Pembrolizumab as Neoadjuvant Treatment in HCC | unknown | Phase 2 | 50 | Kindai UniversityOTHER | 0 | Nov 9, 2017 | clinicaltrials |
| NCT03338166 | Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Nov 9, 2017 | clinicaltrials |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | terminated | Phase 2 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT00321594 | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Nov 6, 2017 | clinicaltrials |
| NCT01217034 | Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib(TACTICS) | unknown | Phase 2 | 228 | Kindai UniversityOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT03326375 | Comparison of SBRTand Repeat TACE for HCC(STH) | unknown | N/A | 80 | Gangneung Asan HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT01213758 | Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT | completed | — | 14 | University of AarhusOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT03314532 | The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma | unknown | N/A | 230 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).(HCC DC CTL) | suspended | Phase 1 / Phase 2 | 100 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00963612 | Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI) | completed | N/A | 80 | University Health Network, TorontoOTHER | 1 | Oct 2, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Apr 25, 2018source: clinicaltrials